Tech Company Financing Transactions
Juno Therapeutics Funding Round
Arch Venture Partners, private investors and Venrock participated in a $134 million Series B funding round for Juno Therapeutics. The round was recorded on 8/5/2014.
Transaction Overview
Company Name
Announced On
8/5/2014
Transaction Type
Venture Equity
Amount
$134,000,000
Round
Series B
Investors
Arch Venture Partners (Robert Nelsen)
Venrock (Anthony Evnin)
Proceeds Purpose
Our funding puts us in a strong position to move forward with multiple CAR-T and TCR therapies and invest in the science that will support continued innovation with these game-changing technologies.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
307 Westlake Avenue North 300
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Website
Email Address
Overview
Juno is a clinical-stage company that brings together three of the world's leading cancer centers -- Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute -- in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hans Bishop
Chief Financial Officer
Steve Harr
Chief Medical Officer
Mark Gilbert
Chief Scientific Officer
Ken Mohler
VP - General Counsel
Barney Cassidy
VP - Human Resources
Robin Andrulevich
VP - Manufacturing
Andy Walker
VP - R & D
Mark Frohlich
VP - Regulatory Affairs
Elizabeth Smith
Browse more venture capital transactions:
Prev: 8/5/2014: OpenSignal venture capital transaction
Next: 8/5/2014: Rebiotix venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs